To date, both the European and the American main oncological guidelines (11, 12) recommend the execution of the BRCA test in all patients with a new diagnosis of high-grade ovarian cancer, to search for somatic and germline mutations of BRCA1/2, and the execution of the HRD test, for the evaluation of the degree of genomic instability of the tumor, so as to identify the patients who would obtain the greatest benefit from PARP-inhibitor therapy, in the context of an increasingly customized and individualized precision medicine. This evidence concerns the gene PARP1 and ovarian carcinoma.